Parkin-mediated mitophagy inhibitors may be tested in PD model systems which exhibit excessive mitophagy, such as PD-causing mutations W403A in PARK2 and A53T in PARK1 (ref. 28). This evidence concerns the gene SNCA and Parkinson disease.